Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13118511 | 0.87 | HRH4 (0.57) | HRH4HRH3 | |
| SCHEMBL360521 | 0.83 | KDM4E (0.54) | KDM4EPOLBPLD1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL27866106 | 0.81 | KDM4E (0.52) | KDM4EPOLBPLD1ALDH1A1MAPT | |
| SCHEMBL23875353 | 0.79 | PLD1 (0.52) | KDM4EPOLBGRIN2BPLD1GRM1 | |
| SCHEMBL20064053 | 0.78 | USP30 (0.46) | KDM4EGRIN2BPLD1GRM1ALDH1A1 | |
| SCHEMBL20064080 | 0.77 | HRH3 (0.40) | KDM4EALDH1A1MAPTHRH4HRH3 | |
| SCHEMBL2005995 | 0.77 | USP30 (0.54) | KDM4EGRIN2BGRM1ALDH1A1USP30 | |
| SCHEMBL29991351 | 0.76 | GRIN2B (0.49) | KDM4EGRIN2BPLD1GRM1ALDH1A1 | |
| SCHEMBL24454273 | 0.76 | HRH4 (0.51) | KDM4EGRIN2BALDH1A1GRIN2DGRIN3B | |
| SCHEMBL25587376 | 0.76 | USP30 (0.53) | GRIN2BGRM1ALDH1A1USP30CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | KDM4E 1653/4885POLB 27/4885GRIN2B 4152/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | KDM4E 1653/4885POLB 27/4885GRIN2B 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.